Immunohistochemistry or IHC
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma
Cytopathology 2020 October 6 [Link] Ben Davidson, Annika Jøntvedt Bock, Arild Holth, Dag Andre Nymoen Abstract Objective: To analyze the expression and clinical role of the phosphatase PTPN1 (PTP1B) in serous effusions. Methods: PTPN1 mRNA expression by quantitative RT-PCR was analyzed in 83 high-grade serous carcinoma (HGSC) and 15 malignant mesothelioma (MM) effusions. PTP1B and…
Read MoreTissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report)
Journal of Translational Medicine 2020 September 4 [Link] Irene Dell’Anno, Elisa Barone, Luciano Mutti, Doris M Rassl, Stefan J Marciniak, Roberto Silvestri, Stefano Landi, Federica Gemignani Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm of the pleura, mainly related to asbestos exposure. As in other solid tumors, malignant cells exhibit high glucose uptake…
Read MoreThe potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas
Human Pathology 2020 September 2 [Link] Sarita Prabhakaran, Ashleigh Hocking, Chankyung Kim, Matthew Hussey, Sonja Klebe Abstract Malignant pleural mesothelioma is associated with asbestos exposure and poor outcomes. The usefulness of immunohistochemistry for diagnosis of sarcomatoid mesothelioma, especially the desmoplastic type, is limited, and more effective markers are required. GATA binding protein 3 (GATA3) has…
Read MoreDeterminants of plasma calretinin in patients with malignant pleural mesothelioma
BMC Research Notes 2020 July 29 [Link] Martin Lehnert, Daniel G Weber, Dirk Taeger, Irina Raiko, Jens Kollmeier, Susann Stephan-Falkenau, Thomas Brüning, Georg Johnen, MoMar-Study Group Abstract Objective: Calretinin is a well-known immunohistochemical tissue marker in the diagnosis of malignant mesothelioma. Promising results also indicate the use in early detection. In the present cross-sectional survey,…
Read MoreTesting for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology
Cancer Cytopathology 2020 July 17 [Link] Martin Chevrier, Sara E Monaco, Jacob A Jerome, Francoise Galateau-Salle, Andrew Churg, Sanja Dacic Abstract Background: A number of ancillary tests have been developed that aid in the diagnosis of mesothelioma in cytology specimens. The aim of this retrospective study was to determine whether testing for BAP1 and CDKN2A/p16…
Read MoreNucleolin and nucleophosmin expression patterns in pulmonary adenocarcinoma invading the pleura and in pleural malignant mesothelioma
Thoracic Cancer 2020 July 16 [Link] Marek Masiuk, Piotr Waloszczyk, Magdalena Lewandowska, Ewa Dobak, Elzbieta Urasinska Abstract Background: Visceral pleural invasion (VPI) in adenocarcinoma of the lung is considered a poor prognostic factor. The purpose of this study was to analyze nucleolin and nucleophosmin expression in pulmonary adenocarcinoma (PA) with VPI and in pleural malignant…
Read MoreQuestioning the Prognostic Role of BAP-1 Immunohistochemistry in Malignant Pleural Mesothelioma: A Single Center Experience With Systematic Review and Meta-Analysis
Lung Cancer 2020 June 21 [Link] Luca Cantini, Federica Pecci, Alberto Murrone, Marco Tomasetti, Cecilia Copparoni, Ilaria Fiordoliva, Francesca Morgese, Silvia Rinaldi, Paola Mazzanti, Corrado Rubini, Alessia Cimadamore, Francesca Barbisan, Riccardo Giampieri, Marina Scarpelli, Lory Santarelli, Rossana Berardi Abstract Introduction: The prognostic role of BRCA1 associated protein-1 (BAP1) expression in malignant pleural mesothelioma (MPM) is…
Read MoreGenomic Profiling of Multiple Primary Cancers Including Synchronous Lung Adenocarcinoma and Bilateral Malignant Mesotheliomas: Identification of a Novel BAP1 Germline Variant
Pathology International 2020 June 24 [Link] Aya Shinozaki-Ushiku, Shinji Kohsaka, Hidenori Kage, Katsutoshi Oda, Kiyoshi Miyagawa, Jun Nakajima, Hiroyuki Aburatani, Hiroyuki Mano, Tetsuo Ushiku Abstract We report a case with a rare combination of synchronous lung adenocarcinoma and bilateral malignant pleural mesotheliomas in a 70-year-old male without asbestos exposure. He metachronously developed peritoneal malignant mesothelioma,…
Read MoreNTRK and ALK Rearrangements in Malignant Pleural Mesothelioma, Pulmonary Neuroendocrine Tumours and Non-Small Cell Lung Cancer
Lung Cancer 2020 May 24 [Link] Jose Luis Leal, Geoffrey Peters, Marcin Szaumkessel, Trishe Leong, Khashayar Asadi, Gareth Rivalland, Hongdo Do, Clare Senko, Paul L Mitchell, Chai Zi Quing, Alexander Dobrovic, Bibhusal Thapa, Thomas John Abstract Objectives: Gene rearrangements involving NTRK1, NTRK2, NTRK3, ROS1 and ALK have been identified in many types of cancer, including…
Read MoreGenomic-based Ancillary Assays Offer Improved Diagnostic Yield of Effusion Cytology With Potential Challenges in Malignant Pleural Mesothelioma
Pathology International 2020 June 15 [Link] Yoshiaki Kinoshita, Makoto Hamasaki, Shinji Matsumoto, Masayo Yoshimura, Ayuko Sato, Tohru Tsujimura, Toshiaki Kamei, Kunimitsu Kawahara, Kazuki Nabeshima Abstract BRCA1-associated protein 1 (BAP1) or methylthioadenosine phosphorylase (MTAP) immunohistochemistry (IHC) or 9p21 fluorescence in situ hybridization (FISH) are useful for the diagnosis of malignant pleural mesothelioma (MPM). However, the effect…
Read More